Access and adherence to medications for the primary and secondary prevention of atherosclerotic cardiovascular disease in Singapore: a qualitative study by Koh JJK, Cheng RX, Yap YC, Haldane V, Tan YG, Teo KWQ, Srivastava A, Ong PS, Perel P, Legido-Quigley H

Subjects: “…Atherosclerotic cardiovascular disease…”
Get full text

Prevalence, awareness, treatment, and risk factor control of high atherosclerotic cardiovascular disease risk in Guangzhou, China by Hui Liu, Weiquan Lin, Weiquan Lin, Kexin Tu, Qin Zhou, Qin Zhou, Chang Wang, Minying Sun, Minying Sun, Yaohui Li, Xiangyi Liu, Guozhen Lin, Sidong Li, Wei Bao

“…BackgroundIdentifying individuals at high risk of atherosclerotic cardiovascular disease (ASCVD) and implementing targeted prevention strategies might be the key to reducing the heavy disease burden in China. …”
Get full text

Comparison of 10-year atherosclerotic cardiovascular disease (ASCVD) risk in metropolitan and rural areas of South of Iran by Mohammad Javad Zibaeenezhad, Mehrab Sayadi, Hossein Pourmontaseri, Davood Khalili, Mojtaba Farjam, Ehsan Bahramail, Nader Parsa, Azizallah Dehghan, Seyyed Saeed Mohammadi, Iman Razeghian-Jahromi, Hamed Bazrafshan drissi, Matin Sepehrinia

Subjects: “…Atherosclerotic cardiovascular disease risk score…”
Get full text

Development of new scores for atherosclerotic cardiovascular disease using specific medical examination items: the Suita Study by Ahmed Arafa, Rena Kashima, Yuka Yasui, Haruna Kawachi, Chisa Matsumoto, Saya Nosaka, Masayuki Teramoto, Miki Matsuo, Yoshihiro Kokubo

Get full text

Associations between nine dietary minerals intake and all-cause mortality in individuals with atherosclerotic cardiovascular disease by Chenglin Duan, Chenglin Duan, Meng Lv, Xintian Shou, Zizhen Chen, Yujie Luan, Yujie Luan, Yuanhui Hu

Subjects: Get full text

Effect of Sarcopenia on 10-Year Risk of Atherosclerotic Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus by Xia LF, Li JB, Tian GS, Jiang WR, Li YS, Lin CY, Qiu HN, Wu F, Wang JJ, Li CJ, Lin JN

Subjects: “…atherosclerotic cardiovascular disease…”
Get full text

Lifetime predicted risk of atherosclerotic cardiovascular disease among an urban cohort: A cross-sectional study by Nikita Maheshbhai Savani, Rajendra B Chauhan, Rajesh K Chudasama

Subjects: “…atherosclerotic cardiovascular disease…”
Get full text

Serum branch-chained amino acids are increased in type 2 diabetes and associated with atherosclerotic cardiovascular disease by Juan Moreno-Vedia, Dídac Llop, Ricardo Rodríguez-Calvo, Núria Plana, Núria Amigó, Roser Rosales, Yaiza Esteban, Josefa Girona, Lluís Masana, Daiana Ibarretxe

“…Using proton nuclear magnetic resonance (1H-NMR), we aimed to study the plasma levels of low-molecular-weight metabolites (LMWMs) in a cohort of 307 patients with metabolic diseases to assess their relationships with type-2 diabetes (T2D) and incident atherosclerotic cardiovascular disease (ASCVD). Methods We conducted a cross-sectional and prospective study. …”
Get full text

Incorporating longitudinal history of risk factors into atherosclerotic cardiovascular disease risk prediction using deep learning by Jingzhi Yu, Xiaoyun Yang, Yu Deng, Amy E. Krefman, Lindsay R. Pool, Lihui Zhao, Xinlei Mi, Hongyan Ning, John Wilkins, Donald M. Lloyd-Jones, Lucia C. Petito, Norrina B. Allen

“…Abstract It is increasingly clear that longitudinal risk factor levels and trajectories are related to risk for atherosclerotic cardiovascular disease (ASCVD) above and beyond single measures. …”
Get full text

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease by Petri T. Kovanen, Alpo Vuorio

Subjects: “…Atherosclerotic cardiovascular disease…”
Get full text

Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors by Michael L. Dansinger, Paul T. Williams, H. Robert Superko, Ernst J. Schaefer

“…Abstract Background and aims Non-high-density (HDL)-cholesterol, low-density lipoprotein (LDL)-particle number, apolipoprotein B, lipoprotein(a) (Lp(a)), and small-dense (sdLDL) and large-buoyant (lbLDL) LDL-subfractions are emerging apo B-containing atherosclerotic cardiovascular disease (ASCVD) risk factors. Current guidelines emphasize lifestyle, including weight loss, for ASCVD risk management. …”
Get full text

Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease by Robert W. Ariss BS, Rajesh Gupta MD

“…Several medications including icosapent ethyl, rivaroxaban, and ezetimibe have been shown to individually improve outcomes in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD) beyond conventional therapy consisting of aspirin and statins. …”
Get full text

ESTIMATED AGGREGATE TREATMENT BENEFIT WITH ADDITION OF MULTIPLE NOVEL MEDICATIONS FOR SECONDARY PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE by Robert W. Ariss, Rajesh Gupta

Get full text

Trends in direct health care costs among US adults with atherosclerotic cardiovascular disease with and without diabetes by Chintal H. Shah, Gregg C. Fonarow, Justin B. Echouffo-Tcheugui

“…Abstract Objective Population-based national data on the trends in expenditures related to coexisting atherosclerotic cardiovascular diseases (ASCVD) and diabetes is scarce. …”
Get full text

Tumor necrosis factor gene polymorphism rs1800629 in patients with atherosclerotic cardiovascular diseases: A review by Elena V. Khazova, Olga V. Bulashova, Elena V. Valeeva

Subjects: Get full text

Optimized Treatment of Refractory Hypercholesterolemia in Patients With Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia With Alirocumab (OPTIMIZE) by Isabella Sudano, Francois Mach, Tiziano Moccetti, Thilo Burkard, Christian Fahe, Alain Delabays, Hans Rickli, Pierre-Frédéric Keller, Jörn Dopheide, Jörn Dopheide, Sereina Bodenmann, Tom Fiolka, Georg Ehret, David Spirk, David Spirk

Subjects: “…atherosclerotic cardiovascular disease…”
Get full text

Current Guideline Risk Stratification and Cardiovascular Outcomes in Chinese Patients Suffered From Atherosclerotic Cardiovascular Disease by Sha Li, Hui-Hui Liu, Yuan-Lin Guo, Cheng-Gang Zhu, Na-Qiong Wu, Rui-Xia Xu, Qian Dong, Jie Qian, Ke-Fei Dou, Jian-Jun Li

“…Background and AimsHeterogeneity exists among patients with atherosclerotic cardiovascular disease (ASCVD) with regard to the risk of recurrent events. …”
Get full text

Premature Atherosclerotic Cardiovascular Disease: Trends in Incidence, Risk Factors, and Sex‐Related Differences, 2000 to 2016 by Diana N. Vikulova, Maja Grubisic, Yinshan Zhao, Kelsey Lynch, Karin H. Humphries, Simon N. Pimstone, Liam R. Brunham

“…Background The incidence of atherosclerotic cardiovascular disease has declined in the past 2 decades. …”
Get full text

Predicted impact of lipid lowering therapy on cardiovascular and economic outcomes of Swedish atherosclerotic cardiovascular disease guideline by Gunilla Journath, Kristina Hambraeus, Emil Hagström, Billie Pettersson, Mickael Löthgren

Get full text

Priorities for Services in Young Patients With Atherosclerotic Cardiovascular Disease and Their Family Members: An Exploratory Mixed-Methods Study by Raymond Y. Cho, BSc, Jian Weng, BSc, Kelsey Lynch, MSc, CGC, Phoebe Ng, BSc, Chad Brown, BSc, Alison M. Hoens, MSc, BScPT, Kevin Barry, Liam R. Brunham, MD, PhD, FRCPC, Simon Pimstone, MD, PhD, FRCPC

“…Background: Optimal design of clinical programs for patients with premature atherosclerotic cardiovascular disease (ASCVD) (men aged ≤ 50 years, women aged ≤ 55 years) requires an understanding of their priorities. …”
Get full text